Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 28, 2026Clinical and Experimental Dermatology

Treatment Trajectories and Dose Optimization of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Real-World Landmark Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MNM A NapolitanoCPChiara PalagianoCPCataldo Patruno

Discussion

Loading...

Member takes

Overview

Retrospective analysis evaluates dose optimization's effects on outcomes in patients with atopic dermatitis, suggesting effective strategies.

Key Points

  • To assess treatment trajectories and clinical outcomes associated with abrocitinib dose management in moderate-to-severe atopic dermatitis.
  • Retrospective single-center observational study
  • Included adult patients with moderate-to-severe atopic dermatitis
  • Utilized a Week 16 landmark approach to classify treatment trajectories.
  • 63.8% of patients initiated treatment with 200 mg abrocitinib
  • Dose escalation occurred in 23.8% of patients due to insufficient efficacy
  • Clinically meaningful reductions in EASI, p-NRS, and DLQI were observed across all treatment groups.

Cite This Study

Napolitano et al. (2026) studied this question.

synapsesocial.com/papers/6a40bae361bb0a67205c6a44https://doi.org/10.1093/ced/llag271
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical and inflammatory determinants of successful abrocitinib dose reduction in atopic dermatitis: a real-world cohort study with implications for treatment optimization2026
  2. 2Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL2026
  3. 3Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)2026
  4. 4Real-World Use of Abrocitinib for Moderate-to-Severe Atopic Dermatitis in the United States Based on Electronic Health Records and Administrative Claims2026
  5. 5Real-World Effectiveness and Safety of Upadacitinib Versus Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study2026